Compare Duolingo Inc (DUOL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Duolingo IncTrade

Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Duolingo Inc vs Recursion Pharmaceuticals Inc — how do they compare? Duolingo Inc trades at $134.6 (market cap $6.34B), while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.81B). The key difference: Duolingo Inc is far larger — about 3.5× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

	DUOL	RXRX
Market Cap	$6.34B	$1.81B
Sector	Technology	Health
52-Week High	$369.19	$6.79
52-Week Low	$90.03	$2.84
Enterprise Value	$5.11B	$1.33B

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

DUOL

Duolingo remains a Hold due to slowing growth and high valuation despite strong cash flow.Seeking Alpha · 1 day agoNeutral Duolingo downgraded to Neutral as revenue growth lags behind strong user gainsSeeking Alpha · 2 days agoBearish View details →

RXRX

Recursion Pharmaceuticals faces slow growth and cash burn despite AI drug discovery partnerships.Seeking Alpha · 1 day agoBearish View details →

About Duolingo Inc

Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.